A taxonomy of model structures for economic evaluation of health technologies

被引:326
作者
Brennan, Alan
Chick, Stephen E.
Davies, Ruth
机构
[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield S14 DA, S Yorkshire, England
[2] INSEAD, Technol & Operat Management Area, Hlth Management Inst, Fontainebleau, France
[3] Univ Warwick, Warwick Business Sch, Coventry, W Midlands, England
关键词
health technology assessment; cost-effectiveness analysis; modelling methodology; simulation; decision tree; Markov model;
D O I
10.1002/hec.1148
中图分类号
F [经济];
学科分类号
02 ;
摘要
Models for the economic evaluation of health technologies provide valuable information to decision makers. The choice of model structure is rarely discussed in published studies and can affect the results produced. Many papers describe good modelling practice, but few describe how to choose from the many types of available models. This paper develops a new taxonomy of model structures. The horizontal axis of the taxonomy describes assumptions about the role of expected values, randomness, the heterogeneity of entities, and the degree of non-Markovian structure. Commonly used aggregate models, including decision trees and Markov models require large population numbers, homogeneous sub-groups and linear interactions. Individual models are more flexible, but may require replications with different random numbers to estimate expected values. The vertical axis of the taxonomy describes potential interactions between the individual actors, as well as how the interactions occur through time. Models using interactions, such as system dynamics, some Markov models, and discrete event simulation are fairly uncommon in the health economics but are necessary for modelling infectious diseases and systems with constrained resources. The paper provides guidance for choosing a model, based on key requirements, including output requirements, the population size, and system complexity. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:1295 / 1310
页数:16
相关论文
共 65 条
[51]   ON A MODEL FOR INTERFERENCE BETWEEN SEARCHING INSECT PARASITES [J].
POLLETT, PK .
JOURNAL OF THE AUSTRALIAN MATHEMATICAL SOCIETY SERIES B-APPLIED MATHEMATICS, 1990, 32 :133-150
[52]   Using simulation for AIDS policy modeling: Benefits for HIV/AIDS prevention policy makers in Vienna, Austria [J].
Rauner M.S. .
Health Care Management Science, 2002, 5 (2) :121-134
[53]  
Ross S.M., 1996, STOCHASTIC PROCESSES
[54]   Assessing quality in decision analytic cost-effectiveness models - A suggested framework and example of application [J].
Sculpher, M ;
Fenwick, E ;
Claxton, K .
PHARMACOECONOMICS, 2000, 17 (05) :461-477
[55]  
Sculpher MJ, 2004, HEALTH TECHNOL ASSES, V8, P1
[56]   MARKOV-MODELS IN MEDICAL DECISION-MAKING - A PRACTICAL GUIDE [J].
SONNENBERG, FA ;
BECK, JR .
MEDICAL DECISION MAKING, 1993, 13 (04) :322-338
[57]   Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling [J].
Spiegelhalter, DJ ;
Best, NG .
STATISTICS IN MEDICINE, 2003, 22 (23) :3687-3709
[58]   Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women [J].
Stevenson, MD ;
Brazier, JE ;
Calvert, NW ;
Lloyd-Jones, M ;
Oakley, JE ;
Kanis, JA .
JOURNAL OF THE OPERATIONAL RESEARCH SOCIETY, 2005, 56 (02) :214-221
[59]   Gaussian process modeling in conjunction with individual patient simulation modeling: A case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis [J].
Stevenson, MD ;
Oakley, J ;
Chilcott, JB .
MEDICAL DECISION MAKING, 2004, 24 (01) :89-100
[60]   Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle [J].
Taylor, RS ;
Drummond, MF ;
Salkeld, G ;
Sullivan, SD .
BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7472) :972-975